Universiteit
Leiden
The Netherlands

PLGA-based particulate vaccine delivery systems for immunotherapy of cancer

Monteiro Garrido Castro e Silva, Ana Luisa

Citation
Monteiro Garrido Castro e Silva, A. L. (2015, December 22). *PLGA-based particulate vaccine delivery systems for immunotherapy of cancer*. Retrieved from https://hdl.handle.net/1887/37169

Version:	Corrected Publisher's Version
License:	Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden
Downloaded from:	https://hdl.handle.net/1887/37169

Note: To cite this publication please use the final published version (if applicable).

Cover Page

Universiteit Leiden

The handle http://hdl.handle.net/1887/37169 holds various files of this Leiden University dissertation.

Author: Monteiro Garrido Castro e Silva, Ana Luisa (Ana Luisa Silva)
Title: PLGA-based particulate vaccine delivery systems for immunotherapy of cancer
Issue Date: 2015-12-22

Stellingen

Behorende bij het proefschrift

PLGA-based particulate vaccine delivery systems for immunotherapy of cancer

1. Encapsulation of antigens in PLGA-nanoparticles results in enhanced MHC class I presentation and $CD8^+$ T cell activation.

This thesis, chapter 4

2. Low-burst release of encapsulated antigen is crucial for efficient MHC class I antigen presentation and $CD8^+$ T cell activation in vivo.

This thesis, chapter 5

3. Encapsulation of synthetic long peptides in nanoparticles is an effective way to achieve endolysosomal targeting and prolonged MHC class I antigen presentation.

This thesis, chapter 6

4. PLGA nanoparticles and/or liposomes loaded with synthetic long peptides do not require Toll-like receptor agonists to induce cellular immune responses.

This thesis, chapter 7

5. Synthetic long peptides antigen is more effectively processed for MHC class I presentation and induce stronger $CD8^+$ T cell responses than protein antigen.

Rosalia et al., Eur J Immunol (43) 2013

6. The size of particulate adjuvants is not only related to the strength, but also the type of immune responses.

Oyewumi et al., Expert Rev Vaccines (9) 2010

7. As most pathogens present multiple Toll-like receptor agonists to antigen-presenting cells, the combination of multiple Toll-like receptor agonists can result in a synergistic effect.

Black et al., Expert Rev Vaccines (9) 2010

8. The key properties of viruses that are responsible for eliciting potent immune responses may be used as a framework for rational vaccine design.

Bachmann et al., Nat Rev Immunol (10) 2010

9. The best way to get something done is to begin.

Anonymous

10. If we knew what it was we were doing, it would not be called research, would it?

Albert Einstein

11. If a favored idea fails a well-designed test, it's wrong. Get over it.

Neil deGrasse Tyson

12. Your questions are false if you already know the answer.

José Saramago, The Stone Raft